Company in its Board Meeting has approved financial results for period ended 31st March,2026
RESULTS
▲ Positive Development
LOW RISK
📅 Filed on BSE: 27 May 2026, 04:30 PM IST · BSE ID: 423b0e6c-0178-4ac2-96e5-62f93ec3fb56
View Original BSE Filing (PDF)
💡
In Simple Terms
The company reported its full-year financial results, showing increased sales and profits compared to the previous year.
🤖 AI Summary
- Concord Drugs Ltd Board approved consolidated financial results for the year ended March 31, 2026.
- Consolidated Net Sales from Operations for FY26 was Rs. 7,873.68 lakhs, compared to Rs. 4,524.46 lakhs in FY25.
- Consolidated Profit After Tax for the year ended March 31, 2026, stood at Rs. 105.50 lakhs.
- Basic Earnings Per Share (EPS) on a consolidated basis was Rs. 0.95 for FY26, up from Rs. 0.34 in FY25.
- Equity share capital increased to Rs. 1,317.50 lakhs as of March 31, 2026, from Rs. 1,000.00 lakhs in FY25.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Consolidated Net Sales from Operations (FY26)
7,873.68 lakhs
73.92%
Consolidated Profit/ (Loss) for the period (FY26)
105.50 lakhs
213.82%
Consolidated Basic EPS (FY26)
0.95 Rs
179.41%
Total Assets (Consolidated FY26)
7,488.76 lakhs
14.96%
Total Equity (Consolidated FY26)
4,851.39 lakhs
42.22%
🏢 How This Affects the Company
The company demonstrated significant growth in its core revenue from operations, indicating an expansion of its market presence or sales volume.
The increase in net sales and profit after tax suggests improved financial performance, contributing to higher earnings per share and other equity.
👥 What This Means For Shareholders
✅
Action Required
No action required from shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the improved financial performance, which contributes to increased basic EPS of Rs. 0.95.
🔍
Management Signal
The approval of the annual financial results signals management's focus on reporting operational and financial performance.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q1 FY27 results — monitor continuation of revenue and profit growth.
Next Board Meeting — observe any strategic decisions or capital allocation plans.
Updates on preferential share issuance — track conversion of warrants if any.
LOW RISK
Filing indicates strong financial growth for the period.
💡 Investor Takeaway
Concord Drugs reported consolidated Net Sales from Operations of Rs. 7,873.68 lakhs for the year ended March 31, 2026, a 73.92% increase from Rs. 4,524.46 lakhs in FY25. Consolidated Profit After Tax grew to Rs. 105.50 lakhs, representing a 213.82% increase from Rs. 33.62 lakhs in FY25.
⚖️ Strengths & Concerns
✅ Positives
- Consolidated Net Sales from Operations grew to Rs. 7,873.68 lakhs in FY26 from Rs. 4,524.46 lakhs in FY25, indicating strong revenue growth.
- Consolidated Profit for the period increased to Rs. 105.50 lakhs in FY26, up from Rs. 33.62 lakhs in the previous fiscal year.
⚠️ Concerns
- Non-current assets decreased to Rs. 2,157.61 lakhs as of March 31, 2026, from Rs. 2,437.97 lakhs on March 31, 2025.
- Current financial liabilities, specifically borrowings, remained high at Rs. 1,179.33 lakhs, indicating continued reliance on short-term debt.
📅 Company Track Record
No previous filings found for this company on ForgeUp to provide historical context. The company recently issued 31,75,000 Equity shares on a preferential basis during the quarter ended December 31, 2025, and allotted 20,25,000 warrants.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What were Concord Drugs Ltd's consolidated net sales from operations for the year ended March 31, 2026?
Concord Drugs Ltd reported consolidated net sales from operations of Rs. 7,873.68 lakhs for the year ended March 31, 2026.
What was the consolidated profit after tax for Concord Drugs Ltd in FY26?
The consolidated profit after tax for Concord Drugs Ltd for the year ended March 31, 2026, was Rs. 105.50 lakhs.
What was the basic earnings per share (EPS) for Concord Drugs Ltd on a consolidated basis for FY26?
Concord Drugs Ltd's consolidated basic earnings per share (EPS) was Rs. 0.95 for the year ended March 31, 2026.
How did Concord Drugs Ltd's total equity change from FY25 to FY26?
Concord Drugs Ltd's total consolidated equity increased to Rs. 4,851.39 lakhs as of March 31, 2026, from Rs. 3,411.36 lakhs as of March 31, 2025.
Questions based on this BSE filing only. For information purposes.